Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SAPPHO
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
- NCT06439693 ↗
- Recruiting
- Dana-Farber Cancer Institute
- Focused
We haven't built an HCP commentary report on SAPPHO (de novo HER2+ metastatic breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SAPPHO so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer Female; Breast Cancer; Breast Cancer Metastatic; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Stage IV Breast Cancer
- Interventions
- Nab-Paclitaxel; Paclitaxel; Docetaxel; Phesgo; T-DM1; Pertuzumab; Trastuzumab Deruxtecan; Trastuzumab Subcutaneous Subcutaneous; Tucatinib; Trastuzumab
- Arms
- HER2+ Breast Cancer · Experimental
- Enrollment
- 72 (estimated)
- Primary outcomes
- Disease Free Survival at 4 Years (DFS4)
- Sponsor
- Dana-Farber Cancer Institute with Translational Breast Cancer Research Consortium, Johns Hopkins University
- Start
- Aug 8, 2024
- Primary completion
- Mar 30, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06439693 · updated Aug 6, 2026